医学临床研究
   Jul. 8, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2024, Vol. 41 Issue (11): 1715-1718    DOI: 10.3969/j.issn.1671-7171.2024.11.024
Original Articles Current Issue | Archive | Adv Search |
Clinical Efficacy of Sulodexide Combined with Epalrestat in the Treatment of Type 2 Diabetes Mellitus Complicated with Diabetic Peripheral Neuropathy
WU Changhao
Department of Endocrine,China Rongtong Medical Health Group Yichang No.154 Hospital,Xinyang Henan 464000
Download: PDF (1228 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】To investigate the clinical efficacy of Sulodexide combined with epalrestat in the treatment of type 2 diabetesmellitus (T2DM) patients with diabetic peripheral neuropathy (DPN).【Methods】A total of 95 T2DM patients with DPN treated in our hospital from February 2020 to March 2023 were selected and divided into control group (receiving epalrestat treatment, n=46) and observation group (receiving Sulodexide treatment on the basis of control group treatment, n=49) according to different treatment methods. The clinical efficacy, clinical score, nerve conduction velocity, glycated hemoglobin(HbA1c), fasting blood glucose (FPG), serological indexes and incidence of adverse reactions were compared between the two groups.【Results】The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the pain, paresthesia, burning sensation, numbness scores and serum malondialdehyde (MDA) and endothelin-1 (ET-1) levels in both groups were lower than before treatment (P<0.05), and the pain, paresthesia, burning sensation, numbness scores and serum MDA and ET-1 levels in the observation group were lower than those in the control group (P<0.05). After treatment, the sensory conduction velocity (SNCV), motor conduction velocity (MNCV) and serum nitric oxide (NO) levels of the median nerve and common peroneal nerve in both groups were higher than before treatment (P<0.05), and the levels of SNCV, MNCV and NO in the median nerve and common peroneal nerve in the observation group were higher than those in the control group (P<0.05). After treatment, the HbA1c and FPG of both groups were lower than before treatment (P<0.05), and the HbA1c and FPG of observation group were lower than those of control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Sulodexide combined with epalrestat is effective in the treatment of T2DM patients with DPN, and can improve blood glucose control, clinical symptoms, oxidative stress index, vascular endothelial function index, nerve conduction velocity, and is safe and reliable.
Key wordsDiabetes Mellitus, Type 2/CO      Diabetic Neuropathies/CO      Anticoagulants/TU      Treatment Outcome     
Received: 04 June 2024     
PACS:  R587.24  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
WU Changhao
Cite this article:   
WU Changhao. Clinical Efficacy of Sulodexide Combined with Epalrestat in the Treatment of Type 2 Diabetes Mellitus Complicated with Diabetic Peripheral Neuropathy[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(11): 1715-1718.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.11.024     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I11/1715
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech